Armed Forces Institute Of Pathology To Conduct NanoViricides Animal Studies Against Bird Fl

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that they have executed a Cooperative Research and Development Agreement (CRADA) with the Armed Forces Institute of Pathology (AFIP). This joint R&D effort will enable AFIP scientists to test the effectiveness of several NanoViricides, Inc. anti-viral nanomedicines against deadly bird flu viruses (H5N1) at their facilities.

"We are very excited to study the effectiveness of nanoviricides against the most current strains of H5N1 in animal models," said lead AFIP scientist Dr. Mina Izadjoo.

The H5N1 bird flu virus continues to spread further across the globe every year, while continuing to mutate. The accumulating mutations make a human pandemic ever more likely. Because the virus is continually changing its genomic structure, creating a vaccine against it is very difficult. It has been predicted that six to nine months will be needed to produce an effective vaccine in the case of a pandemic. Broad-spectrum antivirals that continue to be effective in the face of the mutations in the virus strain will therefore be essential for any effective response to a pandemic.

For a concise up-to-date summary, please visit http://www.cidrap.umn.edu/cidrap/content/influenza/avianflu/biofacts/avflu_human.html